Published in the Korea Biomedical Review & the Korean Doctors’ Weekly
Global health is a growing priority for Korea’s international cooperation agenda as the COVID-19 pandemic has highlighted its well-executed pandemic response, providing opportunities for increased leadership in global health. Korea has stepped up multilaterally, emphasizing the importance of health as a human right and an essential factor for socio-economic development, focusing on equitable access to global public goods. Furthermore, part of the pandemic response fostered technological innovation and unleashed Korea’s competency to develop “commercializable” products and of value to global health. With this said, there will be a growing demand for public procurement on global health products meeting both Korea’s commitment to global health and maximizing equitable access.
As the Program Associate of the Investment Management team at the Research Investment for Global Health Technology Fund (RIGHT Fund), which is an international public-private partnership that supports the R&D of innovative technologies with the capacity to tackle endemic and emerging infectious diseases in developing countries, I recently attended the KAIST Executive Program on International Competitive Bid and Global Procurement Management Program (IGMP). This program educates government agencies and business leaders on the public procurement market to prepare them for entering international competitive bidding. Because I work on the management of R&D projects of RIGHT Fund, my goal for joining this course was to understand the public procurement procedure, especially in the context of global health U.N. procurement agencies such as UNICEF. RIGHT Fund’s goal is to ultimately deliver safe and effective products accessible to those most in need in developing countries.